A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

This study is testing how safe four different medicines are for treating **Relapsed Refractory Multiple Myeloma**, a type of cancer affecting blood cells. There are two parts in the study. In part 1, patients will receive three medicines: Elranatamab, Carfilzomib, and Dexamethasone. In part 2, patients will receive two medicines: Elranatamab and Maplirpacept. Elranatamab is given as a shot under the skin, while others are given through an IV, which means directly into a vein. Each treatment cycle lasts four weeks, and participants will be in the study for about two years.

• Participation lasts around 2 years.
• All participants receive Elranatamab; others depend on the part they join.
• Participants must have prior multiple myeloma treatments and meet specific criteria.

It’s important to note that participants need to be in good health and not have certain other illnesses. This study aims to find the best dose and see if these medicines can help treat this type of cancer safely. Participants will need to visit the study site regularly for check-ups and medicine administration. 💉✨